Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elad Sharon

Showing results (131-140 of 191) with videos related to

Pageof 20
Sort By:
JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2021
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid TumorsNaoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, et al.
Annals of Hematology|November 30, 2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, et al.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Oncotarget|November 20, 2020
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomasGeraldine O'Sullivan Coyne, Shivaani Kummar, Robert S Meehan, et al.
The Lancet. Oncology|March 1, 2023
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshopLalitha K Shankar, Heiko Schöder, Elad Sharon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol JRoisin M Connolly, Victoria Wang, David M Hyman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) StudyNilofer S Azad, Robert J Gray, Michael J Overman, et al.
JAMA Network Open|June 4, 2025
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic DisordersKylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2024
Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi SarcomaKathryn Lurain, Ramya Ramaswami, Irene Ekwede, et al.
Pageof 20

Showing results (131-140 of 191) with videos related to

Sort By:
Pageof 20
JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2021
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid TumorsNaoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, et al.
Annals of Hematology|November 30, 2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, et al.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Oncotarget|November 20, 2020
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomasGeraldine O'Sullivan Coyne, Shivaani Kummar, Robert S Meehan, et al.
The Lancet. Oncology|March 1, 2023
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshopLalitha K Shankar, Heiko Schöder, Elad Sharon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol JRoisin M Connolly, Victoria Wang, David M Hyman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2019
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) StudyNilofer S Azad, Robert J Gray, Michael J Overman, et al.
JAMA Network Open|June 4, 2025
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic DisordersKylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2024
Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi SarcomaKathryn Lurain, Ramya Ramaswami, Irene Ekwede, et al.
Pageof 20